Compugen (CGEN) AI Stock Analysis

• Market Cap: $134.69M
• Dividend Yield: N/A
• Average Volume (3M): 258.60K
• Price to Earnings (P/E): 87.5
• Beta (1Y): 1.61
• Revenue Growth: -48.16%
• EPS Growth: -97.37%
• Country: US
• Employees: 74
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 93,535,355
• 10 Day Avg. Volume: 264,400
• 30 Day Avg. Volume: 258,596
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: 10.08
• Enterprise Value/Gross Profit: 11.58
• Enterprise Value/Ebitda: -2.22
• 1Y Price Target: $8.50
• Price Target Upside: 478.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: $1.50 ▲(2.04% Upside)

Compugen's overall stock score is primarily influenced by its financial performance and earnings call insights. While the company shows potential through strategic collaborations and pipeline advancements, ongoing profitability challenges and valuation concerns weigh heavily on the score. Technical indicators suggest a cautious market sentiment, further impacting the overall assessment.

Positive Factors

Strategic Collaborations

Strong partnerships with major pharmaceutical companies like AstraZeneca provide financial stability and validate Compugen's drug development capabilities, enhancing long-term growth prospects.

Cash Position

A solid cash position ensures Compugen can sustain operations and invest in R&D, supporting its strategic initiatives and providing a buffer against financial volatility.

Pipeline Advancement

Progress in the COM701 trial for ovarian cancer highlights Compugen's innovative approach and potential to address unmet medical needs, strengthening its competitive edge in oncology.

Negative Factors

Revenue Decline

The sharp decline in revenue indicates challenges in achieving consistent income from partnerships and milestone payments, which could impact financial sustainability.

Increased Net Loss

Rising net losses highlight ongoing profitability challenges, potentially limiting Compugen's ability to reinvest in R&D and expand its pipeline without additional funding.

Competitive Pressures

Intense competition in key therapeutic areas could hinder Compugen's market share and revenue potential, requiring strategic differentiation and innovation to maintain its position.

Compugen Business Overview & Revenue Model

Company Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

How the Company Makes Money

Compugen generates revenue through multiple streams, including licensing agreements, research collaborations, and potential milestone payments from its partners. The company typically partners with larger pharmaceutical companies to co-develop its drug candidates, which allows it to receive upfront payments and future royalties based on the sales of successfully commercialized products. Additionally, Compugen may earn revenue from grants and government funding for specific research projects. Significant partnerships with established biopharmaceutical firms enhance its financial stability and contribute to its earnings through shared research efforts and joint development initiatives.

Compugen Financial Statement Overview

Summary

Compugen's financial statements reflect typical challenges of a biotechnology firm, with fluctuating revenue growth and ongoing profitability issues. Improved cash flow management in recent periods is a positive sign, but sustaining profitability and maintaining financial stability remain key risks.

Income Statement

Compugen has shown fluctuating revenue growth, with a positive increase from 2021 to 2023 but a decline in 2024. The consistent negative net income and EBIT margins reflect ongoing challenges in profitability, typical in the biotechnology sector. Despite improvements in gross profit, the company's net profit margins remain negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals a stable equity position but high volatility in debt levels. The debt-to-equity ratio remains low, suggesting manageable leverage. However, the declining equity ratio and fluctuations in stockholders' equity indicate potential risks in maintaining financial stability.

Cash Flow

Cash flow analysis shows significant improvement in operating cash flow and free cash flow by 2024, highlighting better cash management. However, the company experienced negative free cash flow in previous years, raising concerns about long-term cash sustainability. The positive cash flow trend in 2024 is a promising sign of recovery.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.86M	33.46M	7.50M	6.00M	2.00M
Gross Profit	19.93M	31.45M	6.53M	5.32M	1.94M
EBITDA	-14.40M	-12.52M	-35.37M	-34.61M	-31.50M
Net Income	-14.23M	-18.75M	-33.69M	-32.87M	-27.26M
Balance Sheet
Total Assets	115.00M	121.33M	94.18M	132.16M	138.32M
Cash, Cash Equivalents and Short-Term Investments	103.25M	50.69M	83.71M	117.76M	124.43M
Total Debt	2.91M	1.35M	1.93M	2.75M	3.17M
Total Liabilities	60.08M	55.77M	16.50M	25.47M	18.53M
Stockholders Equity	54.91M	65.56M	77.68M	106.69M	119.78M
Cash Flow
Free Cash Flow	49.49M	-36.06M	-34.99M	-23.04M	-28.49M
Operating Cash Flow	49.60M	-35.89M	-34.51M	-22.75M	-28.32M
Investing Cash Flow	-46.25M	35.51M	37.06M	6.62M	-82.17M
Financing Cash Flow	554.00K	3.08M	353.00K	16.84M	108.46M

Compugen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.47
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEN, the sentiment is Positive. The current price of 1.47 is above the 20-day moving average (MA) of 1.40, above the 50-day MA of 1.44, and below the 200-day MA of 1.63, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 57.28 is Neutral, neither overbought nor oversold. The STOCH value of 67.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGEN.

Compugen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	54 Neutral	$452.25M	-2.55	77.89%	―	15.73%	38.73%
CGEN	52 Neutral	$134.69M	87.50	-35.66%	―	-48.16%	-97.37%
SEER	52 Neutral	$124.51M	-1.56	-26.44%	―	12.13%	-8.23%
SLN	48 Neutral	$267.82M	-3.10	-33.81%	―	―	―
PRQR	45 Neutral	$230.42M	-4.80	-59.23%	―	7.59%	-53.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Compugen Corporate Events

Compugen’s Shareholders Approve All Proposals at 2025 Annual Meeting

On September 16, 2025, Compugen Ltd. conducted its 2025 Annual General Meeting of Shareholders, where all proposals were approved by the necessary majority vote. This approval signifies continued shareholder support and could potentially strengthen Compugen’s strategic initiatives and market position in the biotechnology sector.

Compugen Ltd. Announces 2025 Annual General Meeting Details

On August 6, 2025, Compugen Ltd. announced the distribution of its proxy statement to shareholders for the upcoming annual general meeting scheduled for September 16, 2025, in Israel. The meeting will address the election of seven directors, approval of compensation for incoming executives, and re-appointment of the company’s independent accounting firm. This event is significant for stakeholders as it involves key decisions on leadership and financial oversight, impacting the company’s strategic direction and governance.

Compugen Reports Q2 2025 Results and Advances in Immuno-Oncology Trials

Compugen Ltd. reported its second quarter 2025 financial results on August 6, 2025, highlighting significant advancements in its immuno-oncology pipeline. The company dosed the first patient in its MAIA-ovarian trial for COM701 and is preparing to present a pooled analysis of Phase 1 trials at ESMO 2025. Compugen’s partner, AstraZeneca, is progressing with its rilvegostomig program, which could become a significant revenue source for Compugen. Financially, the company maintains a solid position with a cash runway expected to fund operations into 2027, despite a decrease in revenue compared to the previous year.

Compugen Initiates Global Trial for COM701 in Ovarian Cancer

On July 21, 2025, Compugen Ltd. announced the dosing of the first patient in a global trial for COM701, a potential first-in-class anti-PVRIG antibody, aimed at treating relapsed platinum sensitive ovarian cancer. The trial, supported by strong biological rationale and clinical data, seeks to address significant unmet medical needs and could potentially pave the way for COM701’s broader application in ovarian cancer treatment. An interim analysis is planned for the second half of 2026, which could inform future registration paths and combination therapy opportunities.